


CLAIMS

We claim:

1. A compound of formula I



I

- wherein R¹ is C₁₋₆ alkyl, optionally substituted with -OH, -OC₁₋₄ alkyl or het;
 wherein C₁₋₆ alkyl is optionally partially unsaturated;
 wherein het is a radical of a five- or six--membered heterocyclic ring having one or two
 heteroatoms selected from the group consisting of oxygen, sulfur and N;
 or a pharmaceutically acceptable salt, racemate, solvate, tautomer, optical isomer or prodrug
 derivative thereof.
2. A compound of claim 1 wherein R¹ is propyl.
3. A compound of claim 1 wherein R¹ is 3-hydroxypropyl.
4. A compound of claim 1 wherein R¹ is 3-hydroxy-1-propynyl.
5. A compound of claim 1 wherein het is morpholine, thiomorpholine, piperidine,
 piperazine or pyrrolidine.
6. A compound of claim 1 wherein R¹ is 4-morpholinylmethyl.
7. A compound of claim 1 which is
- (a) N-(4-chlorobenzyl)-9-(4-morpholinylmethyl)-7-thioxo-2,3-dihydro-7H-
 [1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide,
- (b) N-(4-chlorobenzyl)-9-(3-hydroxy-1-propynyl)-7-thioxo-2,3-dihydro-7H-
 [1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide,
- (c) N-(4-chlorobenzyl)-9-(3-hydroxypropyl)-7-thioxo-2,3-dihydro-7H-
 [1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide, or

(d) N-(4-chlorobenzyl)-7-thioxo-9-propyl-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide.

8. A compound of claim 1 which is N-(4-chlorobenzyl)-9-(4-morpholinylmethyl)-7-thioxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide.

9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

10. A method of treating or preventing infections by herpesviruses which comprises administering to a mammal in need thereof a compound of claim 1.

11. The method of claim 10 wherein said herpesviruses is herpes simplex virus types 1, herpes simplex virus types 2, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, human herpes viruses 6, human herpes viruses 7 or human herpes viruses.

12. The method of claim 10 wherein said herpesviruses is human cytomegalovirus.


13. The method of claim 10 wherein the compound of claim 1 is administered orally, parenterally or topically.

14. The method of claim 10 wherein the compound of claim 1 is in an amount of from about 0.1 to about 300 mg/kg of body weight.

15. The method of claim 10 wherein the compound of claim 1 is in an amount of from about 1 to about 30 mg/kg of body weight.

16. A method for inhibiting a viral DNA polymerase, comprising contacting the polymerase with an effective inhibitory amount of a compound of claim 1.

17. An intermediates of formula II



II

wherein X is O or S; and R² is optionally partially unsaturated C₁₋₆ alkyl substituted with

5 O-TIPS.

10

10034949.122701